139.34
price down icon3.82%   -5.54
after-market Handel nachbörslich: 139.09 -0.25 -0.18%
loading
Schlusskurs vom Vortag:
$144.88
Offen:
$140.65
24-Stunden-Volumen:
443.63K
Relative Volume:
0.76
Marktkapitalisierung:
$8.13B
Einnahmen:
$633.51M
Nettoeinkommen (Verlust:
$-8.10M
KGV:
-449.48
EPS:
-0.31
Netto-Cashflow:
$131.26M
1W Leistung:
-2.18%
1M Leistung:
-14.34%
6M Leistung:
-2.54%
1J Leistung:
-29.17%
1-Tages-Spanne:
Value
$137.92
$144.32
1-Wochen-Bereich:
Value
$137.92
$153.89
52-Wochen-Spanne:
Value
$113.50
$200.23

Repligen Corp Stock (RGEN) Company Profile

Name
Firmenname
Repligen Corp
Name
Telefon
(781) 449-9560
Name
Adresse
41 SEYON STREET, WALTHAM, MA
Name
Mitarbeiter
1,778
Name
Twitter
@repligen
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
RGEN's Discussions on Twitter

Vergleichen Sie RGEN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Medical Instruments & Supplies icon
RGEN
Repligen Corp
139.34 8.13B 633.51M -8.10M 131.26M -0.31
Medical Instruments & Supplies icon
ISRG
Intuitive Surgical Inc
491.81 176.29B 8.35B 2.32B 1.30B 6.41
Medical Instruments & Supplies icon
BDX
Becton Dickinson Co
231.85 66.57B 20.64B 1.73B 2.94B 6.02
Medical Instruments & Supplies icon
ALC
Alcon Inc
91.37 45.19B 9.91B 1.02B 665.00M 2.05
Medical Instruments & Supplies icon
RMD
Resmed Inc
221.11 32.48B 4.93B 1.25B 1.38B 8.47
Medical Instruments & Supplies icon
BAX
Baxter International Inc
33.44 17.07B 17.28B 108.00M 391.00M 0.20

Repligen Corp Stock (RGEN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-18 Eingeleitet Evercore ISI In-line
2025-02-10 Eingeleitet TD Cowen Buy
2024-12-17 Eingeleitet Canaccord Genuity Hold
2024-11-14 Eingeleitet Wolfe Research Peer Perform
2024-08-28 Eingeleitet Wells Fargo Overweight
2024-06-26 Hochstufung Deutsche Bank Hold → Buy
2024-06-18 Eingeleitet Guggenheim Neutral
2023-12-04 Herabstufung The Benchmark Company Buy → Hold
2023-07-20 Eingeleitet Wells Fargo Overweight
2023-07-05 Fortgesetzt JP Morgan Overweight
2023-03-28 Eingeleitet The Benchmark Company Buy
2022-12-14 Eingeleitet Deutsche Bank Hold
2022-12-07 Eingeleitet RBC Capital Mkts Sector Perform
2022-07-20 Eingeleitet UBS Buy
2021-10-14 Eingeleitet Exane BNP Paribas Outperform
2020-11-10 Eingeleitet KeyBanc Capital Markets Overweight
2020-08-24 Bestätigt H.C. Wainwright Buy
2020-06-30 Bestätigt H.C. Wainwright Buy
2020-05-07 Bestätigt H.C. Wainwright Buy
2020-03-23 Bestätigt H.C. Wainwright Buy
2019-11-15 Eingeleitet Stifel Buy
2019-11-01 Hochstufung First Analysis Sec Outperform → Strong Buy
2019-10-15 Eingeleitet SVB Leerink Outperform
2019-08-28 Bestätigt First Analysis Sec Outperform
2019-08-23 Fortgesetzt Stephens Overweight
2019-07-22 Hochstufung H.C. Wainwright Neutral → Buy
2018-12-17 Hochstufung CL King Neutral → Buy
2018-11-12 Herabstufung CL King Buy → Neutral
2018-09-26 Eingeleitet H.C. Wainwright Neutral
2017-12-08 Eingeleitet Citigroup Buy
2017-12-05 Eingeleitet JP Morgan Overweight
2017-11-13 Eingeleitet CL King Buy
2017-10-02 Hochstufung First Analysis Sec Equal-Weight → Overweight
2017-07-21 Eingeleitet William Blair Outperform
2017-02-13 Hochstufung Piper Jaffray Neutral → Overweight
Alle ansehen

Repligen Corp Aktie (RGEN) Neueste Nachrichten

pulisher
05:35 AM

PNC Financial Services Group Inc. Sells 262 Shares of Repligen Co. (NASDAQ:RGEN) - Defense World

05:35 AM
pulisher
Mar 19, 2025

Repligen Corp director Hunt Anthony sells $4.08 million in stock By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Repligen Corp director Hunt Anthony sells $4.08 million in stock - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Repligen’s SWOT analysis: bioprocessing leader’s stock faces growth and valuation challenges - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Repligen (NASDAQ:RGEN) Coverage Initiated by Analysts at Evercore ISI - Defense World

Mar 19, 2025
pulisher
Mar 19, 2025

Repligen Co. (NASDAQ:RGEN) Shares Sold by Victory Capital Management Inc. - Defense World

Mar 19, 2025
pulisher
Mar 19, 2025

Repligen director Pax Margaret acquires $37,672 in common stock By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

REPLIGEN Director Margaret Pax Acquires 250 Shares - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Evercore ISI sets Repligen stock In Line with $155 price target - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Demystifying Repligen: Insights From 6 Analyst Reviews - Benzinga

Mar 18, 2025
pulisher
Mar 17, 2025

Repligen initiated with an In Line at Evercore ISI - TipRanks

Mar 17, 2025
pulisher
Mar 16, 2025

Repligen Corp (RGEN) Shares Up 5.72% on Mar 17 - GuruFocus.com

Mar 16, 2025
pulisher
Mar 15, 2025

Repligen Corp (RGEN) Shares Up 5.72% on Mar 15 - GuruFocus.com

Mar 15, 2025
pulisher
Mar 14, 2025

REPLIGEN CORP SEC 10-K Report - TradingView

Mar 14, 2025
pulisher
Mar 12, 2025

William Blair Brokers Reduce Earnings Estimates for Repligen - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack - The Globe and Mail

Mar 11, 2025
pulisher
Mar 10, 2025

Oppenheimer & Co. Inc. Purchases New Shares in Repligen Co. (NASDAQ:RGEN) - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Repligen Corporation’s Acquisition of Bioprocessing PAT Device Portfolio from 908 Devices - Global Legal Chronicle

Mar 09, 2025
pulisher
Mar 09, 2025

US Bancorp DE Raises Position in Repligen Co. (NASDAQ:RGEN) - Defense World

Mar 09, 2025
pulisher
Mar 06, 2025

Repligen buying 908 Devices’ Bioprocess Analytics portfolio - BioWorld Online

Mar 06, 2025
pulisher
Mar 06, 2025

Sanctuary Advisors LLC Sells 268 Shares of Repligen Co. (NASDAQ:RGEN) - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Repligen (NASDAQ:RGEN) and Compass Therapeutics (NASDAQ:CMPX) Critical Review - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

Truist Financial Corp Trims Stock Position in Repligen Co. (NASDAQ:RGEN) - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth - AOL

Mar 04, 2025
pulisher
Mar 04, 2025

Leerink maintains Repligen stock Outperform rating, $200 target - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

908 Devices stock jumps on Repligen deal (RGEN:NASDAQ) - Seeking Alpha

Mar 04, 2025
pulisher
Mar 04, 2025

Repligen acquires 908 Devices’ desktop bioprocessing tech - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Repligen acquires 908 Devices’ desktop bioprocessing tech By Investing.com - Investing.com Canada

Mar 04, 2025
pulisher
Mar 04, 2025

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices - Yahoo Finance

Mar 04, 2025
pulisher
Mar 03, 2025

Repligen Co. (NASDAQ:RGEN) Receives Consensus Rating of “Moderate Buy” from Brokerages - Armenian Reporter

Mar 03, 2025
pulisher
Mar 03, 2025

Repligen Co. (NASDAQ:RGEN) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

Global Retirement Partners LLC Has $53,000 Stock Position in Repligen Co. (NASDAQ:RGEN) - Defense World

Mar 02, 2025
pulisher
Feb 27, 2025

Global Hollow Fiber Filtration Market: A Comprehensive Study - openPR

Feb 27, 2025
pulisher
Feb 26, 2025

CIBC Asset Management Inc Acquires 81 Shares of Repligen Co. (NASDAQ:RGEN) - Defense World

Feb 26, 2025
pulisher
Feb 26, 2025

Principal Financial Group Inc. Decreases Position in Repligen Co. (NASDAQ:RGEN) - Defense World

Feb 26, 2025
pulisher
Feb 25, 2025

Repligen’s SWOT analysis: bioprocessing leader’s stock poised for growth - Investing.com

Feb 25, 2025
pulisher
Feb 24, 2025

Repligen stock holds steady after Benchmark maintains rating - Investing.com

Feb 24, 2025
pulisher
Feb 24, 2025

Repligen stock holds steady after Benchmark maintains rating By Investing.com - Investing.com UK

Feb 24, 2025
pulisher
Feb 24, 2025

Repligen (NASDAQ:RGEN) Price Target Raised to $200.00 - Defense World

Feb 24, 2025
pulisher
Feb 24, 2025

Repligen (NASDAQ:RGEN) Price Target Raised to $205.00 - Armenian Reporter

Feb 24, 2025
pulisher
Feb 23, 2025

Repligen (NASDAQ:RGEN) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - Defense World

Feb 23, 2025
pulisher
Feb 23, 2025

Repligen (NASDAQ:RGEN) Earns Buy Rating from HC Wainwright - Defense World

Feb 23, 2025
pulisher
Feb 22, 2025

Repligen (NASDAQ:RGEN) Shares Up 8.1% Following Strong Earnings - Defense World

Feb 22, 2025
pulisher
Feb 21, 2025

Repligen Earnings: Encouraging Guidance Supports Attractive Growth Story - Morningstar

Feb 21, 2025
pulisher
Feb 21, 2025

Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier - Morningstar

Feb 21, 2025
pulisher
Feb 21, 2025

Repligen (RGEN) Beats Q4 Earnings Estimates - MSN

Feb 21, 2025
pulisher
Feb 21, 2025

Repligen's Q4 Earnings Beat Estimates, Revenues In Line - Yahoo Finance

Feb 21, 2025
pulisher
Feb 21, 2025

The Analyst Verdict: Repligen In The Eyes Of 4 Experts - Benzinga

Feb 21, 2025
pulisher
Feb 21, 2025

H.C. Wainwright maintains Buy on Repligen, target at $180 - Investing.com

Feb 21, 2025
pulisher
Feb 21, 2025

Repligen Corporation (NASDAQ:RGEN) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 21, 2025
pulisher
Feb 21, 2025

Canaccord raises Repligen stock target to $170, maintains Hold - Investing.com

Feb 21, 2025

Finanzdaten der Repligen Corp-Aktie (RGEN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$16.28
price down icon 2.34%
$168.81
price up icon 1.61%
$61.01
price down icon 0.75%
medical_instruments_supplies COO
$80.39
price up icon 0.34%
medical_instruments_supplies WST
$227.51
price down icon 1.25%
medical_instruments_supplies BAX
$33.44
price down icon 1.91%
Kapitalisierung:     |  Volumen (24h):